Cheryl Gillett

Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast

Julian Peto, Matthias W. Beckmann, Peter A. Fasching, 2014, PLoS genetics.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Paul Ellis, Nazneen Rahman, Alexander Gutin, 2018, Nature Medicine.

Big Data: the challenge for small research groups in the era of cancer genomics

Anita Grigoriadis, L. Holmberg, A. Grigoriadis, 2015, British Journal of Cancer.

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status

Borivoj Vojnovic, Boris N. Kholodenko, Lan K. Nguyen, 2016, Oncotarget.

Therapeutic Targeting of Integrin αvβ6 in Breast Cancer

Rhian Gabe, Andrew R. Green, Ian O. Ellis, 2014, Journal of the National Cancer Institute.

The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example

Valerie Speirs, Alastair M Thompson, S. Pinder, 2012, Journal of Clinical Pathology.

Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature

Trevor Hastie, Paul Cane, Hongyue Dai, 2008, BMC Cancer.

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer

Paul Ellis, Terence P. Speed, Benjamin Haibe-Kains, 2010, Proceedings of the National Academy of Sciences.

Molecular Cytogenetic Identification of Subgroups of Grade III Invasive Ductal Breast Carcinomas with Different Clinical Outcomes

Jorge S. Reis-Filho, Chris Jones, Andrew Hanby, 2004, Clinical Cancer Research.